

# GO Therapeutics

Using new advances in glycoproteomics, GO Therapeutics uses a platform-based approach to developing antibody-based therapies against clean glycoprotein cancer targets.

With this approach, the company is developing novel, multimodal FIC cancer therapeutics against intractable targets.

## Company profile


Founded: 2014

Founders: Constantine Theodoropoulos, Hans Wandall

Headquarters: Cambridge, MA

## Investors

- Salubris Pharmaceutical Limited



## Partners

### Academic

#### University of Copenhagen

#### University of Pennsylvania

Joint research of a CAR-T targeting a cancer-specific glycoprotein on CD44v6 expressed on multiple solid tumors

### Corporate

#### Xyphos Biosciences Inc, subsidiary of Astellas Pharma Inc

Strategic research collaboration and license agreement to develop novel immuno-oncology therapeutics with high affinity to two different glycoprotein targets and apply these antibodies to a range of therapeutic modalities

#### Roche

License agreement to develop and commercialize a new glyco-targeting bispecific antibody

---

## What makes this company stand out?

- O-glycoproteins with truncated O-glycans are absent from normal tissues but are present in 60-80% of human epithelial cancers, which makes them viable therapeutic targets.
- The company has mapped the expression of truncated O-glycans in >700 tissue cores representing healthy and tumor tissues, showing that surface expression of truncated O-glycans is limited to cancers of epithelial origin, making the cancer-associated truncated O-glycans Tn and STn attractive immunological targets to treat human carcinomas.
- Based on this information, GO Therapeutics is developing a new class of cancer-specific, potent, broad-spectrum therapies, both wholly owned and in collaboration with biopharma partners.
- The company's pipeline includes the ADCs GO-13C3, GO-8H3, GO-STn and GO-C15 against solid tumors and the ECM, as well as multiple early-stage T-cell bispecific (TCB), CAR-T cell and immunokine therapies for solid tumors.

## How will the company's platform benefit patients and their caregivers?

- The company's 'super clean' tumor targets have the potential to produce cancer treatments with a greater therapeutic index, increasing the efficacy of immunotherapies with less damage to healthy tissues.
- Selectively targeting O-glycoproteins could deliver more treatments for patients with many different types of cancer.
- GO Therapeutics pursues partnerships that utilize its platform approach to get treatments to patients faster.

---

## Funding and grants

**September 2017:** Independent funding (U.S.\$5m) from Salubris Pharmaceutical Limited

### IP status and patent filings

- GO Therapeutics wholly owns eight patent families that have counterparts in at least the United States, Europe, Japan, Mainland China, South Korea, Australia and Canada.
- The company co-owns an, as yet, unpublished patent family.

### R&D activity

- GO Therapeutics continues to discover novel glycoprotein targets/antibodies that are the framework for novel ADCs and cell therapies, five of which are in IND-enabling studies as of the start of 2024.

"The frustrating clinical reality is that the possibility of potent and potentially curative cancer therapies is being held back by a lack of suitable targets. GO is mining a rich domain of glycoprotein targets for super clean, novel targets that will unleash the next wave of cancer therapies. GO-based ADCs have the potential to achieve complete responses without debilitating on- and off-target toxicities."

Constantine Theodoropoulos,  
GO Therapeutics CEO and co-founder.